evaluate the impact of Covid-19 on prostate cancer diagnosis in a Spanish setting.

**Methods:** A retrospective review of patients referred for a prostate biopsy at a Spanish tertiary hospital was conducted. A 12-month period before and after the eruption of coronavirus in March–2020 was compared for patients referred for analysis.

**Results:** 752 prostate biopsies were done during two years, 471 (62.6%) from March-2019 to February-2020 and 281 (37.4%) from March-2020 to February-2021. A 40% decrease was observed between periods. Precocmedian PSA level was 27.80 ng/ml and postcodivid was 15.07 ng/ml (p = 0.065). Before Covid-19, first prostate biopsies represented 82.16% of biopsies; during the pandemic it was just 71.53% (p = 0.001). The proportion of patients pre-biopsy MRI increased from 37.79% to 56.23% (p = 8.68E-7). Transperineal fusion biopsies, remained stable (62 vs 75). A significant decrease was observed regarding transrectal biopsies at the clinic, with a fall from 409 to 206 procedures (p = 0.000003). Prostate cancer diagnosis represented was approximately 50% of all biopsies in both periods. Treatment strategies remained unchanged during both periods.

**Conclusions:** Pandemic limitations to accessing healthcare has caused a decrease in the number of primary prostate biopsies, an increase in pre-biopsy MRI and a significant loss of patients diagnosed early with prostate cancer which will have a profound effect on delivery of prostate cancer treatment over the next number of years.

**Reference**

---

### Abstract 4

**Tumour bearing kidneys as potential transplant donors: A UK national online survey**

A. Thwaini1, Wesam Elborani1, Aisling Courtney3, Tim Brown4, Zeeshan Aslam1,2, David Cranston2, David Nichol6

1Department of Urology, Belfast City Hospital, Belfast, Northern Ireland; 2Academic Section of Urology, Ninewells Hospital and Medical School, University of Dundee, Scotland; 3Department of Nephrology, Belfast City Hospital, Belfast, Northern Ireland; 4Department of Transplant Surgery, Belfast City Hospital, Belfast, Northern Ireland; 5Nuffield Department of Surgical Sciences, University of Oxford, Oxford; 6The Royal Marsden Hospital, London

**Introduction:** According to the UK annual kidney-transplant report in March 2018, 4,757 adult patients are on the UK kidney-transplant list, with only 3,272 transplants performed. 1200 patients died while waiting for a transplant. More than 7000 nephrectomy operations were recorded at the British Association of Urological Surgeons (BAUS) audit for 2014. 2900 nephrectomy procedures were performed for cT1 renal cancer. We re-explore the acceptability of utilizing small tumour-bearing kidneys as potential organ donors, after ex-vivo tumour removal and pathology confirming benign pathology or low risk cancer with clear margins.

**Methods:** An online survey was carried out across UK urologists with special interest in renal surgery, transplant surgeons and nephrologists, between November and December 2018. Respondents were asked whether they would consider such kidney for transplantation in selected group of dialysis dependent patients.

**Results:** 110 urologists, 70 nephrologists and 50 transplant surgeons were approached. 60 (55%) urologists, 41 (58.5%) nephrologists and 28 (56%) transplant surgeons responded. 43 (72%), 18 (54%) and 26 (93%) of the urologists, nephrologists, transplant surgeons respectively supported the concept of using these kidneys for selected transplant recipients.

**Conclusion:** There is general acceptance for using those kidneys for transplantation in the UK. This concept has its ethical and logistical challenges, though it’s been performed before. However, this survey will encourage starting a trial that addresses the critical unmet need of kidneys for transplantation.

**Reference**

---

### Abstract 5

**Day-case Transurethral Resection of Bladder Tumour (TURBT): A feasible approach in selected patients**

S. Ippoliti1, N. R. Bhatt1, C. P. Ilie1

1The Queen Elizabeth Hospital, NHS Foundation Trust, King’s Lynn, Norfolk, United Kingdom

**Introduction:** Day-case Transurethral Resection of Bladder Tumour (TURBT) is currently only performed in 18% cases across the United Kingdom [1]. The objective of this study is to determine 30-day readmission rate and morbidity after day-case TURBT in a district general hospital (DGH) and to report patient demographics, quality of TURBT and early recurrence rate as well as patient feedback after day-case TURBT.

**Methods:** A retrospective audit of day-case TURBTs over a three-year period pre-COVID19 (2017–20) was performed. We only included patients who underwent a TURBT and excluded any cystoscopy and biopsy or fulguration. A day-case TURBT pathway is in place in this centre. Feedback was obtained using hospital patient feedback forms.

**Results:** We included 77 patients who underwent TURBT in the day-case theatre, of these 5 patients required in-patient stay after the surgery. Of the remaining 72 discharged on the same day, 8 were readmitted (11%) for Clavien-Dindo I complications. The readmission/failed discharge group had a higher rate of older patients, with higher ASA scores and longer operative times, however resection quality and tumour characteristics were not different from the day-case TURBTs. All patients reported an overall positive experience (good or very good).

**Conclusion:** In the first of its kind audit reporting patient feedback after day-case TURBT, the data obtained can provide us and other centres adopting day-case TURBTs guidance to employ better patient selection to reduce readmission rates. Hence, day-case TURBT can be a feasible option in appropriately selected patients, with a suitable pathway in place.

**Reference**

---

### Abstract 6

**Analysing cause of death during follow up for non-muscle invasive bladder cancer: Is there a role for watchful waiting?**

Yuhao Zhang1, Mahmoud Nossier1, Gerald Collins1, James Dyer1

1Stepping Hill Hospital, Stockport, United Kingdom

**Introduction:** Most patients with bladder cancer have non-muscle invasive disease (NMIBC), requiring multiple invasive procedures during follow-up. Surveillance guidelines do not adjust for increasing age or frailty. We aim to evaluate the influence of frailty on the natural history of NMIBC.

**Method:** Patients who died between 1/1/2017–1/1/2020 with bladder cancer and underwent a flexible cystoscopy within 2 years were identified via clinical coding. Notes were reviewed to establish relevant clinical parameters and follow-up procedures. Frailty was